Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PDSBthis companyPDS Biotechnology Corporation	$1.12	-1.04×	3.86×	0×	-0.86×	-89.5%	0.0%	0.0%	0.0%	-372.9%	-116.5%	-77.7%	1.83×	0.32×	-5.91×	2.98×	0.0%	2	-44.34	2	C
ANVSAnnovis Bio, Inc.	$0.90	-2.47×	4.22×	0×	-1.79×	-22.9%	0.0%	0.0%	0.0%	-171.2%	-170.2%	-36.0%	0×	0.68×	0×	5.8×	0.0%	1	-18.04	2	C+
ATNMActinium Pharmaceuticals, Inc.	$1.57	-1.25×	5.42×	471.4×	0.12×	0.8%	100.0%	-40274.4%	-37652.2%	-432.6%	-81.4%	-58.2%	0.22×	1.4×	0×	6.2×	0.0%	4	-8.02	5	S-
INMBINmune Bio, Inc.	$1.14	-0.84×	1.76×	829.46×	-0.39×	-44.6%	100.0%	-61738.0%	-91866.0%	-195.3%	-125.7%	-57.0%	0.04×	0.52×	0×	3.55×	0.0%	1	-9.17	2	C+
OKUROnKure Therapeutics, Inc.	$2.78	-0.66×	0.7×	0×	0.33×	63.3%	0.0%	0.0%	0.0%	-105.9%	-110.9%	-132.3%	0.01×	1×	0×	10.28×	0.0%	2	6.84	3	B
TPSTTempest Therapeutics, Inc.	$0.41	-0.45×	1.79×	0×	-0.48×	-172.7%	0.0%	0.0%	0.0%	-393.9%	-179.5%	-225.2%	1.22×	-0.02×	-128.38×	2.5×	0.0%	1	-53.69	2	C
Peer median	—	-0.84×	1.79×	0×	-0.39×	-22.9%	0.0%	0.0%	0.0%	-195.3%	-125.7%	-58.2%	0.04×	0.68×	0×	5.8×	0.0%	1	-9.17	2	—